Conflicting results with lubeluzole in stroke

Abstract

Two international, randomised, double-blind, placebo-controlled, phase III trials of the neuroprotective agent lubeluzole in patients with stroke have generated conflicting outcomes. Compared with placebo, a significant improvement was seen in functional outcome in patients receiving lubeluzole in the US/Canadian Lub-Int-9 trial, but not in the European/Australian Lub-Int-5 trial. The results of the 2 trials, and the possible reasons for the differences seen, were discussed during the American Heart Association’s 22nd Annual Joint Conference on Stroke and Cerebral Circulation [ Anaheim, US; February 1997 ].